BioXcel Therapeutics files 8-K with buried material changes

FilingFirehose Daily · · 10 filings flagged · archive · RSS

232 8-K filings crossed the tape in the past 24 hours; three items stand out for scope or body language.

Top 3

  • BioXcel Therapeutics (CIK 1720893) filed an 8-K disclosing item 2.03 (creation of direct financial obligation) and 3.01 (material agreement), with subsidiary cost/financing detail buried under 1.03.
  • Crinetics Pharmaceuticals (CIK 1658247) filed a complex 8-K spanning 1.02, 2.01, 3.01, 3.03, 5.01–5.03, and 9.01, suggesting broad corporate action or restructuring with governance and financial items nested under 1.01.
  • cbdMD, Inc. (CIK 1644903) filed 8-K items 1.01, 5.03, 7.01, and 9.01, with bankruptcy/receivership notice language coded under 1.01.

Paid subscribers see 7 more flagged filings + sector signals — upgrade for $9/mo

FilingFirehose Daily · 2026-09-02

Paid subscribers see 7 more flagged filings + cross-sector signal

Upgrade for $9/mo →

Free tier: top 3 filings every morning. One-click unsubscribe. No spam.